Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy.
about
A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay.Adherence to recommendations by infectious disease consultants and its influence on outcomes of intravenous antibiotic-treated hospitalized patients.Pharmacoeconomics of linezolid.The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms.New therapeutic agents for resistant Gram-positive infections.Role of linezolid in the treatment of orthopedic infections.Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review.Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era.Emerging drugs for complicated skin and skin-structure infections.Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agentsClinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective.Antibacterial susceptibility patterns and cross-resistance of methicillin resistant and sensitive staphyloccus aureus isolated from the hospitalized patients in shiraz, iranDevelopment of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.
P2860
Q33246169-5E0FEEF9-3344-4EE9-A156-BF168779FB67Q34472375-B45FFE5A-4D6A-46C5-A3F3-3E38D568C4F0Q34765976-33E462C4-392F-48F8-90C9-D3612C05A5E4Q35873712-FF2E4551-21BA-45BB-8F2C-04BA0D8A3B00Q35917308-4CDD1C04-747B-4B39-9F97-CB68CFEC4520Q36162348-9E16337F-EB46-445D-9F27-7D5BC370BFE3Q36181397-518AD978-73FD-45E6-A78C-274222F95BCFQ36352808-935E0E62-FEF4-41B4-836D-29547FFC6AC8Q36967265-5A9D5B82-ACA2-409B-91A4-043C0C8EE6B0Q37765900-AEF23036-2F57-4BB9-ABAC-D33AA7A3EB42Q38898545-DE66A4E9-843A-42F6-A928-745ACFA52F50Q38939096-84AF0DA6-9BA0-4C8A-B991-ECB99702C2ACQ42593938-F8927057-345D-482C-9BD6-14252260A24AQ46027436-0D9244A9-31DC-4566-9E1F-0DDDAC5473FE
P2860
Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Cost-minimization analysis and ...... atient oral linezolid therapy.
@en
Cost-minimization analysis and ...... atient oral linezolid therapy.
@nl
type
label
Cost-minimization analysis and ...... atient oral linezolid therapy.
@en
Cost-minimization analysis and ...... atient oral linezolid therapy.
@nl
prefLabel
Cost-minimization analysis and ...... atient oral linezolid therapy.
@en
Cost-minimization analysis and ...... atient oral linezolid therapy.
@nl
P2093
P356
P1476
Cost-minimization analysis and ...... atient oral linezolid therapy.
@en
P2093
Anthony J France
Dilip Nathwani
Gavin D Barlow
John Morrison
Katherine Ajdukiewicz
Kirsteen Gray
Peter Davey
P304
P356
10.1093/JAC/DKG061
P407
P577
2003-02-01T00:00:00Z